Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a common neurodegenerative disease in the elderly and is the most common type of dementia. AD is mostly gradual onset, and involves slow, progressive mental decline, accompanied by personality changes; the incidence of AD gradually increases with age. The etiology of AD is unknown, although it is currently believed to be related to abnormal deposition of amyloid β-protein (Aβ) in the brain, hyperphosphorylation of microtubule-associated protein tau, and the release of various cytokines, complements, activators and chemokines by cells. MicroRNAs (miRNAs) are a class of highly conserved non-coding RNAs that regulate gene expression at the post-transcriptional level, and manipulate the functions of intracellular proteins and physiological processes. Emerging studies have shown that miRNA plays an important role in regulating AD-related genes. MiR-132 is known as “NeurimmiR” due to its involvement in numerous neurophysiological and pathological processes. Accumulating pre-clinical results suggest that miR-132 may be involved in the progression of Aβ and tau pathology. Moreover, clinical studies have indicated that decreased circulating miR-132 levels could be used a potential diagnostic biomarker in AD. Here, we review the pathogenic role of miR-132 activity in AD, and the potential of targeting miR-132 for developing future therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519 · cited 1×
“Furthermore, C1q is a major protein in the classical complement cascade, and is highly expressed in synaptic regions of the CNS in AD patients (Bialas and Stevens, 2013).”
BackgroundRetractedComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“It has been reported that, in mouse models of AD, C1q levels were increased and associated with synaptic loss before apparent plaque deposition (Hong et al., 2016), and inhibition of C1q expression reduced the number of phagocytic microglia, and may be involved in early synaptic loss (Stevens et al.”
BackgroundThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Cryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061 · cited 1×
“A large number of specific miRNAs are reduced during AD development, which may be involved in the pathogenesis of AD by affecting the abnormal aggregation of tau protein (Fitzpatrick et al., 2017; Nisbet and Götz, 2018).”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 10×
“It has been shown that miR-132 is involved in regulating Aβ and BACE1 expression.”
BackgroundInfluentialTau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 3×
“The Effects of miR-132 on Tau Protein Abnormal aggregation of tau protein is involved in the pathogenesis of AD, and the most common pathological changes in AD patients are tau protein phosphorylation, abnormal precipitation and aggregation of tau protein, resulting in the formation of NFTs (Congdon and Sigurdsson, 20…”
BackgroundHomeostatic regulation of MeCP2 expression by a CREB-induced microRNA
Klein, M. E., Lioy, D. T., Ma, L., Impey, S., Mandel, G., & Goodman, R. H. (2007) · Nature Neuroscience · doi:10.1038/nn2010 · Cited by 444
Age-related changes in microRNA levels in serum
Hooten, N. N., Fitzpatrick, M., Wood, W. H., De, S., Ejiogu, N., Zhang, Y., Mattison, J. A., Becker, K. G., Zonderman, A. B., & Evans, M. K. (2013) · Aging · doi:10.18632/aging.100603 · Cited by 329 · cited 1×
“For example, miRNAs in plasma can bind to high-density lipoproteins to form a stable structure and thus exist in peripheral blood (Noren Hooten et al., 2013; Turchinovich et al., 2013).”
BackgroundZhang, Z., Liu, X., Schroeder, J. P., Chan, C.-B., Song, M., Yu, S. P., Weinshenker, D., & Ye, K. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.243 · Cited by 242
Cited by
Biological aging processes underlying cognitive decline and neurodegenerative disease
Gonzales, M. M., Garbarino, V. R., Pollet, E., Palavicini, J. P., Kellogg, D. L., Kraig, E., & Orr, M. E. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158453 · Cited by 367
Ryu, I. S., Kim, D. H., Ro, J.-Y., Park, B.-G., Kim, S. H., Im, J.-Y., Lee, J.-Y., Yoon, S. J., Kang, H., Iwatsubo, T., et al. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110603 · Cited by 45
Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease
Arora, T., Prashar, V., Singh, R., Barwal, T. S., Changotra, H., Sharma, A., & Parkash, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02950-z · Cited by 37
The role of microRNA-485 in neurodegenerative diseases
Ryu, I. S., Kim, D. H., Cho, H.-J., & Ryu, J.-H. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 25
Differentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis
Noronha, O., Mesarosovo, L., Anink, J. J., Iyer, A., Aronica, E., & Mills, J. D. (2022) · Genes · doi:10.3390/genes13061034 · Cited by 21
Metadata
- Authors
- Zhang, M., & Bian, Z.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2021-05-24
- Volume
- 15
- Pages
- 687973-687973
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W3165350110
- Cited by
- 55
- References
- 17
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target. https://app.cochat.ai/papers/10.3389/fnins.2021.687973
- The paper
- Zhang, M., & Bian, Z. (2021). Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2021.687973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.